Enter your login e-mail to the account
Search
- The genetic profile is determinating the choice of treatment of de-novo patients with chronic lymphocytic leukemia
MUDr. Zuzana Sninská, PhD., prof. MUDr. Angelika Bátorová, PhD., MUDr. Jozef Lukáš, PhD.
(2/2024, Review articles ) - Chronic lymphocytic leukemia - how to treat a patient with relapsed or refractory disease in the era of signaling pathway inhibitors
MUDr. Firas Farkaš, PhD.
(1/2022, Case reports ) - Acalabrutinib, a new Bruton's tyrosine kinase inhibitor in first line CLL treatment
MUDr. Zuzana Sninská, PhD., prof. MUDr. Angelika Bátorová, PhD.
(2/2023, Review articles ) - Treatment of chronic lymphocytic leukemia with second-generation Bruton›s tyrosine kinase inhibitors – retrospective analysis and clinical experience
MUDr. Firas Farkaš, PhD., MUDr. Zdenka Štefániková, prof. MUDr. Angelika Bátorová, PhD.
(6/2025, Original articles ) - Treatment of indolent B-cell lymphomas
MUDr. Veronika Ballová
(2/2014, Main topic )













